Changes in Beneficial Ownership · 4

iBio, Inc.

IBIONASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Oct 15, 2026Accepted Oct 15, 2026, 6:32 PM EDTFiling CIK 1420720Accession 0001104659-26-116320

View company →Permanent SEC source ↗

Structured filing — 4

tm2627695-4_4seq1.xml

Open full document ↗

Filing details

Report period: 2026-10-14
Issuer: iBio, Inc.
Issuer CIK: 0001420720
Trading symbol: IBIO

Reporting owner 1

Name: Arkowitz David
Reporting owner CIK: 0001296999
Relationship: Director
Address: C/O IBIO, INC., 11750 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO, CA, 92121

Derivative transactions

Derivative transactions · 1 reported row
Security	Conversion / exercise price (USD)	Transaction date	Code	Amount	A / D	Price (USD)	Exercisable	Expires	Underlying security	Underlying shares	Owned after	Ownership
Stock Option (right to buy)^[F1]	0.78	2026-10-14	A · Form 4	38,000^[F1]	A	0	^[F1]	2036-10-13	Common Stock	38,000	38,000	D

Table key

A · Form 4: Acquisition by grant, award or otherwise under Rule 16b-3(d)
A: Acquired
D: Direct

Footnotes

F1: The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.↩ 1 ↩ 2 ↩ 3

Signature 1

Signed: /s/ Marc Banjak, Attorney-in-fact
Date: 2026-10-15

Company context

iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Current securities

IBIONASDAQ · EQUITY · Current

Get the free weekly BCS email.